Periprocedural antiplatelet medication assessed by VerifyNow for neuroendovascular treatment: Comparison of prasugrel with clopidogrel.
Kosuke NambuKouichi MisakiTakehiro UnoTaishi TsutsuiTomoya KamideMitsutoshi NakadaPublished in: Interventional neuroradiology : journal of peritherapeutic neuroradiology, surgical procedures and related neurosciences (2023)
Maintenance dose PRAS further decreased the PRU value and reached the optimal range in more cases than CLP during the perioperative period of neuroendovascular treatment. Ischemic complications significantly increased in the 208 < PRU group.